Abnormal PALB2 expression or mutation increases CRC cell sensitivity to DNA-damaging chemotherapeutics (e.g., oxaliplatin) and correlates with CRC risk and prognosis (44). This evidence concerns the gene PALB2 and colorectal carcinoma.